Miltenyi Biotec, a known name in biomedical solutions, signed a letter of intent with the Translational Health Science and Technology Institute (THSTI), an autonomous body under the Department of Biotechnology, Ministry of Science and Technology.
The collaboration, announced during THSTI’s 15th Foundation Day, is set to advance the development of innovative cell and gene therapies targeting cancer and sickle cell disease.
The partnership aims to harness the complementary strengths of both organizations to enhance research and development in cell and gene therapies. Key focus areas include capacity building, technology transfer, training programs, and joint research initiatives, all of which will contribute to creating new medical therapies.
As reported by biospectrumindia.com, the letter of intent was signed by Sivakumar Natarajan, Interim Managing Director of Miltenyi Biotec, India; Dr. Prudwidhar S, Country Medical Affairs Director at Miltenyi Biotec; and Prof. Ganesan Karthikeyan, Executive Director of BRIC-THSTI.
Sivakumar Natarajan highlighted the significance of the partnership, stating, “Annually, Miltenyi Biotec’s technologies assist in treating over 10,000 patients with cell products. Our collaboration with THSTI aims to deliver new therapies to patients with critical unmet medical needs, particularly in areas where conventional treatments have been inadequate”.
Prof. Ganesan Karthikeyan added, “Our collaboration with Miltenyi Biotec marks a significant advancement in THSTI’s translational research efforts. By combining our advanced scientific expertise and clinical trial capabilities, we strive to provide cutting-edge, accessible cancer treatments tailored to our population’s needs”.